(Q46447343)

English

Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients

scientific article published in May 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

immunohistochemistry

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

author name string

Thiele J

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Kvasnicka HM

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Schmitt-Graeff A

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Kriener S

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Engels K

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Staib P

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Ollig ES

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Keller C

8

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Fokkema S

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Griesshammer M

10

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Waller CF

11

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Hansmann ML

13

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

publication date

1 May 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

46

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

540-550

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

STI571: targeting BCR-ABL as therapy for CML.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Quantitative monitoring of BCR/ABL transcript during STI-571 therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Chronic myeloid leukemia: current treatment options

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Identification of apoptotic cells by formamide-induced dna denaturation in condensed chromatin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Identifiers

10.1111/J.1365-2559.2005.02119.X

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46447343&oldid=2112011865"